[2] It is one of 42 French hospital equipped with the da Vinci Surgical System.

[3] Research at CHU Rennes has included a study of the efficacy of nalmefene.

[4][5] In 2016, a facility run by the private contract research organization Biotrial, running clinical trials required patients to be admitted to CHU Rennes.

[6] The facility ran a phase one study into a new drug being developed by Bial that targets the human endocannabinoid system.

[7] The study failed catastrophically, leaving six subjects hospitalized and one brain dead.